Create Account

One Health helps you track and understand your health simply.

Create Account

One Health helps you track and understand your health simply.

Lamotrigine Level (Blood)

Immunology & Autoimmune

Lamictal levelLamotrigine, serumLTG

Review status

Currently under review

Pending specialist review and validation.

What it shows

The lamotrigine level test measures the amount of lamotrigine in your blood. Lamotrigine is a medication used to prevent seizures and to help stabilize mood in bipolar disorder. Measuring the drug level shows how your body absorbs, distributes, and clears the medicine.

A sample is usually drawn just before your next dose, known as a trough, so the result reflects the lowest routine level in your system. Your care team uses this information to tailor dosing, especially when starting treatment, adjusting doses, or if other medicines are added.

Why it matters

If the level is too low for you, the medicine may not control seizures or mood symptoms. If the level is too high, side effects such as dizziness, blurred vision, nausea, balance problems, or rash are more likely. Because lamotrigine is processed in the liver and influenced by other drugs and hormones, your level can change even when your dose does not.

Your clinician may order this test when you start or change lamotrigine, during pregnancy and after delivery, if you begin or stop interacting medicines, or if you have symptoms suggesting the level is not right. The goal is a level that matches your individual response and safety profile.

Understanding your results

Your clinician will interpret the result in the context of when the blood was drawn, your dose timing, your symptoms, and other medications. If the result is lower than expected for you, they may confirm timing, check for missed doses, and consider gradual dose adjustments. If it is higher than expected, they may assess side effects, look for interactions, and adjust dose or dosing schedule.

Do not change your dose on your own. Contact your care team if you develop new neurologic symptoms or a rash, or if you become pregnant. Levels often decrease during pregnancy and can rebound after delivery, so planned monitoring helps keep treatment both effective and safe.

Reference ranges

420 umol/L
All sexes
0 days – 150 years

Reference intervals vary by laboratory, analyzer, methodology, population, and units. The ranges shown here are for education only. Always interpret your results against the reference interval printed on your own lab report.

Factors that could impact Lamotrigine Level (Blood)

  • Timing of blood draw

    Levels are most useful when drawn as a trough, typically just before the next scheduled dose. Non‑trough samples can appear higher or lower and may lead to misleading interpretation.

  • Drug interactions

    Valproate can raise lamotrigine levels, while enzyme inducers such as carbamazepine, phenytoin, phenobarbital, primidone, and rifampin can lower them. Estrogen‑containing contraceptives often reduce levels; sudden changes in these therapies can shift levels.

  • Pregnancy and hormones

    During pregnancy, lamotrigine is cleared faster and levels often fall; after delivery, levels can rise toward or above pre‑pregnancy values. Hormonal therapies can also alter clearance.

  • Liver and kidney function, age

    Reduced liver function can decrease clearance and raise levels. Kidney impairment and older age may modestly affect handling of the drug, requiring closer monitoring.

  • Adherence and formulation changes

    Missed doses, taking extra doses, or switching between brands or generics can change levels. Let your clinician know about any changes so results are interpreted correctly.

  • Sample handling and method

    Incorrect tube type, delayed processing, or different laboratory methods can affect results. Using the same lab and consistent collection procedures improves comparability over time.

2026

References

  1. McGill University Health Centre. (2018, April 11). Lamotrigine (Task CD 697402). Laboratory reference ranges.
  2. Patsalos, P. N., Berry, D. J., Bourgeois, B. F., Cloyd, J. C., Glauser, T. A., Johannessen, S. I., ... Tomson, T. (2008). Antiepileptic drugs: Best practice guidelines for therapeutic drug monitoring. Epilepsia, 49(7), 1239–1276.
  3. National Institute for Health and Care Excellence. (2022). Epilepsies in children, young people and adults: Diagnosis and management (NICE Guideline NG217).
  4. GlaxoSmithKline. (2023). Lamictal (lamotrigine) prescribing information.